{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30","upperLimit":"58","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Complete response (CR)\n\n\\- Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow.\n\nStringent complete response (sCR) - A CR plus normal FLC ratio and no clonal cells in bone marrow\n\nNear complete response (nCR) A CR, with the persistence of original monoclonal protein\n\nVery good partial response (VGPR)\n\n\\- Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component \\<100 mg per 24 h\n\nPartial response (PR)\n\n* ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h.\n* a ≥50% decrease in the difference between involved and uninvolved FLC levels\n* or a ≥50% reduction in plasma cells is required in place of M-protein, if ≥30% at baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 75 mg/m\\^2 IV day 1 and 2 Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Maximum Tolerated Dose, Dose Level 4"}],"paramType":"NUMBER","populationDescription":"All participants registered to Dose Level 4 (the Maximum Tolerated Dose (MTD)) were eligible for the Phase II Primary Endpoint. This group included the 6 patients registered to Phase I, Dose Level 4 and the 49 participants registered to the Phase II portion.","reportingStatus":"POSTED","timeFrame":"Up to 6 cycles of treatment","title":"Confirmed Response Rate (Dose Level 4) Reported as the Percentage of Patients Achieving a Confirmed Response (sCR, CR, VGPR, or PR).","type":"PRIMARY","unitOfMeasure":"percentage of participants"}